
Overview
Rachel Larosa is a Neuromusculoskeletal Medicine specialist and a Neurologist practicing medicine in Baltimore, Maryland.
Her clinical expertise encompasses Spinocerebellar Ataxia Type 7, Episodic Ataxia with Nystagmus, Spinocerebellar Ataxia Type 17, and Boucher-Neuhauser Syndrome.
Dr. Larosa is board certified in American Board Of Psychiatry And Neurology - Neurology, 2023 and American Board Of Psychiatry & Neurology - Neuromuscular Medicine, 2024. Dr. Larosa is currently accepting new patients.
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
16 South Eutaw Street, Floor 3, Baltimore, MD 21201
National Institute Of Arthritis And Musculoskeletal And Skin Diseases
Dr. Andrew Mammen, MD is a Neurology Specialist in Baltimore, MD. He is affiliated with Johns Hopkins Bayview Medical Center. Dr. Mammen is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Myositis, Polymyositis, Dermatomyositis, and Necrotizing Myopathy (NM). Dr. Mammen is board certified in MD State Medical License 2004-2023. Dr. Mammen is currently accepting new patients.
Johns Hopkins Outpatient Center
Arens Taga is a neurologist specializing in neuromuscular diseases, with a particular focus on amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. His clinical work aims to improve the quality of care for patients with ALS through biomarker-based, precision medicine approaches that refine disease stratification and facilitate more targeted and efficient enrollment in clinical trials. As a clinician-scientist, Dr. Taga uses patient-derived induced pluripotent stem cells to model ALS, uncover novel disease mechanisms and identify therapeutic targets that are translatable to clinical trials. In recognition of his work in ALS, Dr. Taga was awarded the 2025 Richard Olney Clinician Scientist Development Award, which honors early-career physician-scientists dedicated to advancing ALS research. Dr. Taga earned his medical degree from the School of Medicine and Surgery at the University of Parma, Italy, where he also completed his neurology residency. He subsequently trained at The Johns Hopkins University, completing a postdoctoral research fellowship in the neuromuscular division, an internal medicine internship, a neurology residency and a neuromuscular clinical fellowship. Dr. Taga is highly rated in 6 conditions, according to our data. His clinical expertise encompasses 15q11.2 Microdeletion, Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Cluster Headache. Dr. Taga is board certified in American Board Of Psychiatry And Neurology. Dr. Taga is currently accepting new patients.
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy. Dr. Blakeley is board certified in American Board Of Psychiatry And Neurology. Dr. Blakeley is currently accepting new patients.
Frequently Asked Questions about Dr. Rachel L. Larosa
How do I make an appointment with Dr. Rachel L. Larosa?
You can book an appointment with Dr. Rachel L. Larosa by calling their office at 410-328-4323. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Rachel L. Larosa a top-rated expert for Spinocerebellar Ataxia Type 7?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rachel L. Larosa is classified as an Experienced expert for Spinocerebellar Ataxia Type 7, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Rachel L. Larosa specialize in?
While Dr. Rachel L. Larosa is a Neuromusculoskeletal Medicine, they have specific expertise in Spinocerebellar Ataxia Type 7, Episodic Ataxia with Nystagmus, and Spinocerebellar Ataxia Type 17. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neuromusculoskeletal Medicine.
Does Dr. Rachel L. Larosa accept my insurance?
Dr. Rachel L. Larosa accepts most major insurance plans, including Aetna and CareFirst. We recommend calling the office directly at 410-328-4323 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Boucher-Neuhauser SyndromeDr. Larosa isExperienced. Learn about Boucher-Neuhauser Syndrome.
- Dentatorubral-Pallidoluysian AtrophyDr. Larosa isExperienced. Learn about Dentatorubral-Pallidoluysian Atrophy.
- Episodic Ataxia with NystagmusDr. Larosa isExperienced. Learn about Episodic Ataxia with Nystagmus.
- Spinocerebellar Ataxia Type 1Dr. Larosa isExperienced. Learn about Spinocerebellar Ataxia Type 1.
- Spinocerebellar Ataxia Type 11Dr. Larosa isExperienced. Learn about Spinocerebellar Ataxia Type 11.
- Spinocerebellar Ataxia Type 17Dr. Larosa isExperienced. Learn about Spinocerebellar Ataxia Type 17.
- Spinocerebellar Ataxia Type 27Dr. Larosa isExperienced. Learn about Spinocerebellar Ataxia Type 27.
- Spinocerebellar Ataxia Type 3Dr. Larosa isExperienced. Learn about Spinocerebellar Ataxia Type 3.
- Spinocerebellar Ataxia Type 31Dr. Larosa isExperienced. Learn about Spinocerebellar Ataxia Type 31.
- Spinocerebellar Ataxia Type 7Dr. Larosa isExperienced. Learn about Spinocerebellar Ataxia Type 7.

